
SMi reports:Envisagenics will be presenting latest case study on RNA-therapeutics for Triple Negative Breast Cancer
Envisagenicswill be presenting the latest case study on day one of the conference discussing:
Case study: Discovery and development of RNA-therapeutics for Triple Negative Breast Cancer
Maria Luisa Pineda, CEO and Co-founder, Envisagenics
Dr. Maria Luisa Pineda is the co-founder and CEO of Envisagenics, Inc. a biotech spinout of Cold Spring Harbor Laboratory that integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific splicing variants as therapeutic targets. Envisagenics has leveraged its SpliceCore® software platform for therapeutic development with its first pipeline of assets in triple negative breast cancer.
The event brochure with the full agenda and speaker line-up is available to download: www.oligonucleotide.co.uk/phqpr4
Oligonucleotide Therapeutics and Delivery
Main conference: 16th – 17th
September 2020
London, UK
For media queries please contact Jinna
Sidhu at hsidhu@smi-online.co.ukor
call +44 (0)20 7827 6088
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that
specializes in Business-to-Business Conferences, Workshops, Masterclasses and
online Communities. We create and deliver events in the Defence, Security,
Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on
having access to the world’s most forward-thinking opinion leaders and
visionaries, allowing us to bring our communities together to Learn, Engage,
Share and Network. More information can be found at http://www.smi-online.co.uk
Leave a Reply